Morgan Stanley raises Alector stock price target on milestone credit
Morgan Stanley raised its price target for Alector Inc. (ALEC) to $3.00 from $2.00, citing milestone credits for AL050. The stock trades at $1.99 with a $222M market cap. The firm adjusted R&D expenses and EPS estimates, with GAAP EPS forecasted as negative for 2026-2028. Alector partnered with Genentech for AL050, a Parkinson's therapy, but Mizuho maintained a $1.50 target. Analysts see no profitability this year.
How this was made
The 30-second read
Why it matters
The analyst upgrade and partnership credit provide fresh, material information that could drive the stock higher.
Market read
Analyst target raise and partnership credit may boost ALEC's price in the short term.
What to watch
Potential regulatory delays for AL050 and the reliance on future FDA approvals.
Background
Morgan Stanley upgraded Alector (NASDAQ:ALEC) with a new $3.00 price target, citing a $100 M milestone credit tied to its AL050 partnership with Genentech.
Ticker impact
Morgan Stanley raised its price target on Alector to $3.00 and highlighted a new $100 million milestone credit for its AL050 therapy partnership with Genentech.
likely modest upside as the market prices in the higher target and partnership validation
The price target increase and $100 M milestone credit provide fresh, material information that could lift the stock.
Market effects
Positive signal for biotech firms developing neuro‑degenerative therapies.
U.S. biotech sector may see modest gains.
Highlights growing collaboration between U.S. biotech and large pharma.
Counterpoint
The partnership may not translate into near‑term revenue, and the stock remains heavily loss‑making.
Key entities
- companyAlector Inc.
Biotech company developing AL050 for Parkinson's disease.
- companyGenentech
Subsidiary of Roche partnering with Alector on AL050.
